Ismail Selcuk

Ismail Selcuk

Auto-generated profile, based on publicly available information

Ismail Selcuk

Univ Hlth Sci Turkey, Abdulhamid Han Training & Res Hosp, Dept Cardiovasc Surg, Istanbul, Turkiye

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2021 in Medeniyet Medical Journal
Verified
Journal Article
Open access
MSMurat Selçuk
Murat Selçuk
TCTufan Cinar
Tufan Cinar
FŞFAYSAL ŞAYLIK
FAYSAL ŞAYLIK
SDSelami Doğan
Selami Doğan
ISIsmail Selçuk
Ismail Selçuk
AOAhmet L. Orhan
Ahmet L. Orhan
Inflammation plays an important role in the initiation of postoperative atrial fibrillation (PoAF) in individuals undergoing cardiac surgery, Thus, this study aimed to investigate the predictive value of the systemic immune inflammation index (SII) to develop PoAF in such patients. In total, 391 consecutive patients undergoing an isolated coronary artery bypass grafting (CABG) were retrospectively analyzed. PoAF was defined according to the current guideline. The SII is determined using the following equation: neutrophil (N) × platelet (P) ÷ lymphocyte (L). The incidence of PoAF in the present study was 24% (n=97 cases). Multivariate logistic regression analysis revealed that the SII was an independent predictor of PoAF (Odds ratio: 1.002 95% confidence interval: (1.001-1.002), p807.8 with 60.8% sensitivity and 80.9% specificity [area under the curve (AUC): 0.7107]. The AUC value of SII in detecting PoAF was much greater than the AUC values of both the neutrophil to lymphocyte ratio (NLR) and the platelet to lymphocyte ratio (PLR) (AUC: 0.6740 and AUC: 0.6426, respectively). This study revealed that SII was an independent predictor of PoAF in patients who were operated on for isolated CABG. Additionally, SII had a better discriminative ability for PoAF compared to either NLR or PLR among these cases.

1 January 2022 in Brazilian Journal of Cardiovascular Surgery
Verified
Journal Article
Open access
ISİsMail Selçuk
İsMail Selçuk
HSHüseyin Sicim
Hüseyin Sicim
ÜSÜmmühan Nehir Selçuk
Ümmühan Nehir Selçuk
BGBülent Barış Güven
Bülent Barış Güven
AYAhmet Turan Yılmaz
Ahmet Turan Yılmaz
In this study, we aimed to present three different methods for symptomatic aberrant right subclavian artery (ARSA) surgery. We identified 11 consecutive adult patients undergoing symptomatic and/or aneurysmal ARSA repair between January 2016 and December 2020. Symptoms were dysphagia (n=8) and dyspnea + dysphagia (n=3). Six patients had aneurysm formation of the ARSA (mean diameter of 4.2 cm [range 2.8 - 6.3]). All data were analyzed retrospectively. Median age of the patients (7 females/4 males) was 55 years (range 49 - 62). The first four patients (36.4%) underwent hybrid repair using thoracic endovascular aortic repair (TEVAR) and bilateral carotid-subclavian artery bypass (CScBp). Three patients (27.2%) were treated by open ARSA resection/ligation with left mini posterolateral thoracotomy (LMPLT) and right CScBp. And the last four patients (36.4%) underwent ARSA resection/ligation with LMPLT and ascending aorta-right subclavian artery bypass with upper mini sternotomy (UMS). Two of the four patients who underwent TEVAR + bilateral CScBp had continuing dysphagia cause of persistent esophageal compression. Brachial plexus injury developed in one of three patients who underwent LMPLT + right CScBp. Pleural effusion treated with thoracentesis alone was observed in one of four patients who underwent UMS + LMPLT. Among the symptomatic and/or aneurysmal ARSA treatment approaches, surgical and hybrid methods are used. There is still no consensus on how to manage these patients. In our study, we recommend the UMS + LMPLT method, since the risk of complications with anatomical bypass is less, and we have more successful surgical results.


26 March 2022
Verified
Book Chapter
Closed access
BGbülent barış güven
bülent barış güven
ISİsMail Selçuk
İsMail Selçuk
Periferik arter hastalığı (PAH), genellikle ateroskleroz kaynaklı olarak kalp ve beyin dışındaki arterlerde meydana gelen darlık ve tıkanıklıklarla karakterize yaygın bir sağlık sorunudur. Hastalığın en belirgin semptomu olan ağrı, hastaların hareket kabiliyetini kısıtlayarak yaşam kalitesini ciddi şekilde düşürmektedir. PAH yönetiminde temel strateji, sigarayı bırakma, diyabet ve hipertansiyon kontrolü gibi risk faktörlerinin modifikasyonunu içermektedir. Tedavi yaklaşımları non-farmakolojik, farmakolojik ve cerrahi yöntemler olarak sınıflandırılır. Başlangıçta egzersiz programları ve hastalıklı ekstremitenin kalp seviyesinin altında tutulması gibi yöntemler önerilir. İlaç tedavisinde yürüme mesafesini artırmak ve semptomları hafifletmek amacıyla Silostazol, Naftidrofuril ve Pentoksifilin gibi ajanlar kullanılırken, şiddetli iskemik ağrılarda opioid analjeziklere başvurulabilmektedir. İlaçların yetersiz kaldığı durumlarda sempatektomi veya revaskülarizasyon (anjiyoplasti, stent veya baypas) gibi girişimsel yöntemler devreye girer. Erken teşhis ve multidisipliner bir ağrı yönetimi, uzuv kaybı riskini minimize etmek ve hasta konforunu artırmak için kritiktir. Peripheral arterial disease (PAD) is a common health condition characterized by narrowing and occlusion in arteries outside the heart and brain, typically caused by atherosclerosis. Pain, the most prominent symptom of the disease, severely reduces the quality of life by limiting patients' mobility. The primary strategy in PAD management involves the modification of risk factors, such as smoking cessation and the control of diabetes and hypertension. Treatment approaches are classified into non-pharmacological, pharmacological, and surgical methods. Initially, exercise programs and techniques such as keeping the affected limb below heart level are recommended. In pharmacological treatment, agents like Cilostazol, Naftidrofuryl, and Pentoxifylline are used to increase walking distance and alleviate symptoms, while opioid analgesics may be utilized for severe ischemic pain. In cases where medication is insufficient, interventional methods such as sympathectomy or revascularization (angioplasty, stenting, or bypass) are employed. Early diagnosis and multidisciplinary pain management are critical to minimizing the risk of limb loss and enhancing patient comfort.

24 April 2019 in Cardiovascular Surgery and Interventions
Verified
Journal Article
Closed access
ISİsMail Selçuk
İsMail Selçuk

26 March 2022
Verified
Book Chapter
Closed access
ISİsMail Selçuk
İsMail Selçuk
Vazoplejik sendrom, açık kalp cerrahisi ve kardiyopulmoner baypas (KPB) sonrası görülen, düşük sistemik vasküler direnç ve normal/yüksek kalp debisi ile karakterize bir şok tablosudur. Patofizyolojisi sepsise benzer şekilde inflamatuar yanıt, nitrik oksit (NO) aşırı üretimi ve vazopressin eksikliği gibi mekanizmalarla açıklanır. Tedavide birinci basamak seçenek katekolaminler (özellikle norepinefrin) olsa da, yüksek dozların morbiditeyi artırması nedeniyle katekolamin dışı ajanlar kritik öneme sahiptir. Vazopressin, katekolamin ihtiyacını azaltması ve NO etkilerini dengelemesiyle öne çıkan ilk yardımcı ajandır. Dirençli vakalarda metilen mavisi ve hidroksikobalamin, NO yolunu inhibe ederek hemodinamik stabilite sağlar. C vitamini, tiamin ve steroid kombinasyonu antioksidan ve sinerjik etkileriyle değerlendirilirken, anjiyotensin II doğrudan vazokonstriksiyon amacıyla kullanılır. Güncel yaklaşım, toksisiteyi önlemek için katekolamin ve katekolamin dışı ajanların düşük dozlarda rasyonel ve dengeli bir kombinasyonunu savunmaktadır. Erken müdahale ve protokole dayalı yönetim, morbidite ve mortalite oranlarını düşürmede anahtar rol oynar. Vasoplegic syndrome is a form of shock characterized by low systemic vascular resistance and normal/high cardiac output occurring after open heart surgery and cardiopulmonary bypass (CPB). Its pathophysiology is similar to sepsis, involving mechanisms such as inflammatory response, overproduction of nitric oxide (NO), and vasopressin deficiency. While catecholamines (especially norepinephrine) are considered first-line treatment, non-catecholamine agents are critical because high doses increase morbidity. Vasopressin is the primary adjunctive agent, notable for reducing catecholamine requirements and balancing NO effects. In refractory cases, methylene blue and hydroxocobalamin provide hemodynamic stability by inhibiting the NO pathway. The combination of Vitamin C, thiamine, and steroids is evaluated for its antioxidant and synergistic effects, while angiotensin II is used for direct vasoconstriction. Current approaches advocate for a rational and balanced combination of low-dose catecholamine and non-catecholamine therapies to avoid toxicity. Early intervention and protocol-based management play a key role in reducing morbidity and mortality rates.